Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224991 | 1.00 | OPRD1 (0.47) | OPRD1AVPR1A | |
| SCHEMBL3222261 | 0.79 | AVPR1A (0.46) | OPRD1AVPR1A | |
| SCHEMBL3222255 | 0.79 | AVPR1A (0.46) | OPRD1AVPR1A | |
| SCHEMBL3217025 | 0.78 | OPRD1 (0.47) | OPRD1AVPR1A | |
| SCHEMBL3262024 | 0.76 | OPRD1 (0.46) | OPRD1AVPR1A | |
| SCHEMBL3262026 | 0.76 | OPRD1 (0.43) | OPRD1AVPR1A | |
| SCHEMBL3262022 | 0.76 | OPRD1 (0.46) | OPRD1AVPR1A | |
| SCHEMBL3219618 | 0.75 | SCD (0.47) | OPRD1AVPR1A | |
| SCHEMBL3220069 | 0.75 | AVPR1A (0.46) | OPRD1AVPR1A | |
| SCHEMBL3220076 | 0.75 | AVPR1A (0.46) | OPRD1AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | OPRD1 1267/4885AVPR1A 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.